Nonhormonal Treatment of Menopausal Vasomotor Symptoms.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Role of menopause in the development of cardiovascular disease in women.Open heart · 2026
   Review
2. Utilization of fezolinetant for the treatment of moderate-to-severe vasomotor symptoms of menopause in a real-world setting.Menopause (New York, N.Y.) · 2026
   Article
3. Women with PCOS have a later menopausal transition and a lower prevalence of menopausal symptoms at age 46: A population-based birth cohort study.Acta obstetricia et gynecologica Scandinavica · 2026
   Article
4. American Medical Women's Association's commitment to advancing menopausal health equity and awareness.Frontiers in reproductive health · 2026
   Article
5. Precision pharmacology in menopause: advances, challenges, and future innovations for personalized management.Frontiers in reproductive health · 2025
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors.

Funding

Abstract

PubMed holds no abstract for this paper.